We wish to investigate what makes in vitro expanded γδ T cells skew in an IL-17-producing direction using cytokine cocktails, co-culture with different cancer cell lines or supernatants from these. The overall amount of γδ T cells in the periphery is normally 0.5-10% in healthy donors, but it is unknown how many of these are capable of producing IL-17.
Studies have suggested that loss-of-function mutations in the filaggrin gene are associated with increased nickel allergy in humans. However, the immune response involved in this has not yet been characterized. Thus in this study, we investigated the immune responses in filaggrin-deficient flaky tail (ft/ft) mice compared to wild type (WT, C57BL/6 and Balb/c) mice following epicutaneous exposure to nickel. We used a model for contact hypersensitivity, in which ft/ft mice and WT mice were sensitized and challenged with nickel by repeated exposure of the ears to 10% NiCl 2 in petrolatum. The local immune response was analyzed by measurements of ear thickness and expression of proinflammatory cytokines. Furthermore, T cell responses within the draining lymph nodes were analyzed by flow cytometry. A significant increase in ear swelling upon nickel challenge was found in nickel-sensitized ft/ft mice compared to WT mice. Furthermore, nickel exposure caused significantly higher levels of IL-1β in the ears of filaggrin-deficient mice as compared to WT mice. Finally, ft/ft mice sensitized and challenged with nickel had significantly higher numbers of Th1/Tc1 and Th17 cells within the draining lymph nodes in comparison to WT mice. Taken together, we show that nickel elicits a stronger local and adaptive immune response in ft/ft mice compared to WT mice.
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Current influenza vaccines are directed towards the surface proteins hemagglutinin and neuroaminidase providing an antibody-mediated immunity. High variability of these proteins results in costly annual evaluation and production of new vaccines without providing protection against heterosubtypic strains or upcoming pandemic variants. Consequently, there is a need for a new universal influenza vaccine strategy that can provide a basal protection when the conventional vaccines fail. In contrast to the surface proteins, the internal proteins of influenza A are highly conserved. Using one of these, nucleoprotein, encoded in an adenovirus construct (AdNP) we have induced a CD8 T-cell response, which provide heterosubtypic protection. Further, by vaccinating both systemically and locally mice were completely protected against challenge from influenza for at least 8 months post vaccination.
To increase the breadth of the vaccine we have investigated the potential of other conserved influenza proteins as vaccine targets with the intention of making a "vaccine cocktail" by combining the constructs in one vaccination. PB1 expressed from an adenovirus (AdPB1) elicits about the same number of antigen-specific CD8 T cells in mice as AdNP. However, the PB1 directed T cell response protects only 25% of vaccinated mice. We found that one of the underlying reasons for this lack of protection from AdPB1 vaccination relates to a significantly lower in vivo cytotoxicity of these cells compared T cells induced by AdNP. It is important to consider these results and to further evaluate why some epitopes induce a more protective response than others in future vaccine design. T cells of high functional avidity sense and respond to low levels of antigen, and their superior protective efficacy was originally described using CD8 T cells cultured in vitro with low levels of antigen that displayed higher avidity as well as anti-tumor and anti-viral efficacy compared to low avidity T cells cultured with high antigen concentrations. Selectively priming high avidity T cells by low vaccine doses has proven very difficult. We show for the first time that functionally high avidity CD4, but not CD8, T cells can be selectively primed in vivo by low concentrations of antigen in the strong crosspriming liposomal cationic adjuvant formulation (CAF09) DDA/TDB or DDA/MMG/pIC from SSI. Increased functional avidity observed after low-dose vaccinations correlated with lower surface expression of PD-1/CTLA-4/Fas and higher per cell IFN-gamma production compared to low avidity CD4 T cells, and CD4 T cell avidity was dependent on IL-15. Importantly, high avidity CD4 T cells offered superior protection in a murine model of latent infection with Mycobacterium tuberculosis compared to low avidity T cells. Furthermore, adoptive transfers of HIV-specific CD4 T cells of high functional avidity in combination with TCR transgenic HIV-specific CTLs conferred superior protection against viral (recombinant vaccinia-HIV) challenge compared to TCR-Tg CTLs alone or in combination with low avidity CD4 T cells. The invention of purification of peripheral blood mononuclear cells (PBMCs) by gradient centrifugation was a milestone and has been a central technique in the majority of in vitro studies of human T cells. In order to obtain reliable results, it is essential that the purification procedure does not affect the cells. However, we have found that T cells purified by gradient centrifugation downregulate the protein TXNIP, a few hours after purification despite a lack of activation. TXNIP is a proposed cell cycle inhibitor. Downregulation of a cell cycle inhibitor would suggest that T cell purification by gradient centrifugation renders the T cells "primed" and possibly easier to activate subsequently.
The downregulation of TXNIP was not caused by blood drawing, centrifugation, or direct contact with density media. These observations suggest that the downregulation of TXNIP is induced by the gradient centrifugation itself, and that this is a general phenomenon since it was observed using 3 different kinds of density media.
Since TXNIP is a proposed cell cycle inhibitor, the fact that it is downregulated in T cells following gradient centrifugation would suggest that the method leaves the T cells primed and possibly easier to activate in subsequent experiments. It is important for researchers isolating T cells by gradient centrifugation to be aware that the cells are affected and do not accurately reflect the status of T cells in circulation.
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Comparing the stability and activity of recombinant IFN3 and IFN4 Every year 3-4 million people become infected with hepatitis C virus (HCV) and of those almost 85% develop a chronic infection because they fail to clear the virus. Recently, it was shown that people with a functional IFNL4 gene have a lower chance of clearing the virus than people with a non-functional IFNL4 gene. The reason behind this correlation is currently not understood although a causal relationship between the activity of the IFN4 protein and poor HCV clearance has been demonstrated. IFN4 belongs to the type III IFNs together with IFN1, -2, and -3. However, it differs from the others not only by its low sequence similarity but also by its impaired secretion. This impairment is not due to a weak signal peptide, as swapping the signal peptides between IFN3 and -4 had no effect on secretion. When we purified IFN3 and -4, we found that IFN4 is far more difficult to refold in vitro than IFN3 suggesting that the poor secretion of IFN4 could be due to an inherent problem of folding the protein. Because such a problem could also mean that IFN4 could be less stable than other type III IFNs, we decided to compare the stability of recombinant IFNλ3 and IFNλ4. Our results demonstrate that IFNλ4, like IFNλ3, is surprisingly stable once it has folded properly. Treatment accessibility is limited due to high cost [2] and development of a preventive vaccine has proven difficult, partly due to the high mutagenic rate of the virus [3] [4] [5] . Recent studies of HCV antibody resistance have revealed important information about the barrier to escape for several clinically promising human monoclonal antibodies (HMAb) [6, 7] . Here, we co-cultured the novel HMAb AR5A with the neutralization sensitized HVR1-deleted viruses H77/JFH1 ΔHVR1 and J6/JFH1 ΔHVR1 , encoding envelope protein of HCV genotypes 1 and 2, respectively. Interestingly, the path to resistance depended on the isolate. Specifically, we showed that mutation L665W increased AR5A resistance for H77/JFH1, whereas both the mutation L665S and the compensatory mutation S680T were necessary to generate resistance for J6/JFH1. We showed that the site 665 is an important site for AR5A binding and mutations in this site conferred resistance across genotypes 1-6 of HCV. Finally, we observed several cases for which L665W affected neutralization susceptibility against other clinically important HMAbs AR3A and AR4A. Thus, our results revealed important information about resistance for different genotypes, indicating that HCV can overcome the AR5A barrier to resistance in a genotype-specific manner. Elevated titers of IgG antibodies in the cerebrospinal fluid (CSF) are seen in the autoimmune diseases multiple sclerosis and neuromyelitis optica (NMO, in acute relapses). These autoantibodies come either from blood or are produced in the central nervous system. Disruption of blood-or CSFbrain barriers and/or tissue damage can result in access to parenchymal tissue and thereby to specific antigen. Encounter of autoantibodies with specific antigen can lead to hypersensitivity reactions and pathology. Localization of such pathology determines clinical outcomes.
We hypothesized that antibody in CSF can be directed to specific sites in brain by pre-established injury.
A unilateral non-specific injury was made to the brain of C57Bl/6 mice. One day post injury mice received an intrathecal injection into the CSF via cisterna magna of human IgG, either from NMO patients (NMO-IgG) or healthy donors, with/without human complement. Two days post injury brains were collected for histology.
Even though non-specific deposition of human IgG could be detected in both hemispheres, the unilateral injury site showed increased deposition of human IgG compared to the corresponding area in the contralateral hemisphere. Complement-dependent pathology was observed at the targeted site but only in mice that received NMO-IgG.
Stereotactic tissue injury specifically induces deposition of intrathecally-injected autoantibodies and pathology proximal to the injury site, and thus directs antibody trafficking in the brain. TL1A is a proinflammatory cytokine of the TNF family, with the closest sequence identity to TNFα.
Role of Type I Interferon in Neuromyelitis Optica
It is upregulated in the serum of patients with chronic inflammatory diseases, such as Crohn's disease and Rheumatoid arthritis (RA). Furthermore, neutralization of TL1A in animal models of inflammatory bowel disease (IBD) or RA ameliorates disease pathology. This empathises a pivotal role of TL1A in the pathogenesis of inflammatory diseases. Previously, we have shown that TL1A knock-out (KO) mice given low-fat diet display less visceral adipose tissue than wild-type mice and that this phenotype was associated with changes in the gut microbiota. The aim of this study is to determine how TL1A influence on the establishment of adipose tissue, especially whether TL1A's impact on adiposity is mediated through its capacity to regulate inflammation or whether the previously described changes in the gut microbiota affect the energy uptake and thereby adiposity. To assess whether TL1A impact on adiposity was mediated through gut microbiota changes, TL1A KO mice were revitalised in a germ-free environment, and the adiposity was evaluated. To evaluate TL1A's impact on inflammation two approaches were applied. Mice were either injected with biologically active TL1A to increase adiposity or TL1A KO mice were fed highfat diet and leukocytes residing in adipose tissue were analysed by flow cytometry and histology.
Interestingly, TL1A's effect on adiposity was independent of gut microbiota as germ-free TL1A KO mice had a lower adiposity than wild-type mice. Furthermore, TL1A injection resulted in increased adiposity as well as infiltration of leukocytes in the adipose tissue, thereby indicating a more direct effect of TL1A on the establishment of adipose tissue.
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The hepatitis C virus (HCV) is a global public health problem, as a great fraction of patients develop a chronic infection, which may lead to a progressive hepatic fibrosis, cirrhosis and liver cancer. MMP23 is a metalloproteinase expressed by a subset of melanomas. It has been shown that tumors expressing high levels of MMP23 comprise fewer tumor-infiltrating lymphocytes (TIL) and that there is correlation between high levels of MMP23 and an overall worse clinical outcome.
MMP23 has a ShK toxin-like protein domain that has been shown to block Kv1.3 potassium channels. Potassium channels are important for the activation and proliferation of T cells since the channels maintain the calcium homeostasis in the cell. We hypothesize that melanoma cells can suppress effector memory T cells by upregulating MMP23, which blocks Kv1.3 potassium channels on the T cells, and thereby inhibit the anti-tumor response.
Using CRISPR/Cas9, we have successfully created and validated two guide RNAs for MMP23, which target exon 5 or exon 7. By co-transfecting with plasmids expressing the guide RNAs, we have effectively knocked out exon 6, which encodes the ShK toxin-like protein domain. We have thereby created a MMP23 knock out tumor cell line, incapable of blocking the Kv1.3 potassium channel. Functional studies will be conducted to see if T cells have an improved anti-tumor response towards the knock out cell line compared to wild type. We will then move into a humanized mouse model to study the T cell response in vivo. This will hopefully result in novel insight into the immunosuppressive mechanisms of MMP23.
Background: Adoptive T cell transfer (ACT) for treatment of ovarian cancer (OVC) have recently been initiated at Center for Cancer Immune Therapy, Herlev Hospital. However, a major challenge of ACT is inefficient homing of tumor infiltration lymphocytes (TILs) to the tumor site. We hypothesized that by genetic engineering of TILs to increase expression of appropriate chemokine receptors, we would be able to increase the recruitment to the tumor. We tested this by I) Mapping key ovarian tumor chemokines and measuring expression of the corresponding chemokine receptors on TILs and II) studying migration of receptor transduced T cells towards a chemokine source in vitro.
Results:
We found that CCL2, CCL22, CXCL10, CXCL16 and IL-8 were pronounced chemokines of ovarian tumors. Among a panel of corresponding chemokine receptors, we found that CCR2, CCR4, and CXCR2 were only expressed by a small fraction of TILs. Hence, an inverse relationship between chemokine and chemokine receptor expression were found for the three axes CCL2/CCR2, CCL22/CCR4 and IL-8/CXCR2 in ovarian cancer. Based on these results, we showed successful enhanced migration of CCR4-transduced T cells towards its ligand, CCL22.
Conclusion and Perspective:
Low expression of essential chemokine receptors may be responsible for the inadequate homing of TILs to ovarian tumors. We found that genetic engineering to increase expression of appropriate chemokine receptors is a feasible strategy for optimizing migration. For further insight into the clinical relevance we are currently exploring correlations between patient's chemokine receptor expression, chemokine concentrations in blood and ascites, and patient survival. The vaccine has been confirmed to bind poly I:C by electrophoretic mobility shift assay.
Furthermore, binding to murine dendritic cells has also been confirmed. Currently, optimizations of the vaccine production are on-going. Preliminary results will be presented.
